000 04510nam a22004575i 4500
001 978-0-387-68969-2
003 DE-He213
005 20250710084008.0
007 cr nn 008mamaa
008 100301s2008 xxu| s |||| 0|eng d
020 _a9780387689692
_a99780387689692
024 7 _a10.1007/978-0-387-68969-2
_2doi
082 0 4 _a614.5999
_223
100 1 _aCoukos, George.
_eeditor.
245 1 0 _aOvarian Cancer
_h[recurso electrónico] :
_bState of the Art and Future Directions in Translational Research /
_cedited by George Coukos, Andrew Berchuck, Robert Ozols.
264 1 _aNew York, NY :
_bSpringer New York,
_c2008.
300 _bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aAdvances in Experimental Medicine and Biology,
_x0065-2598 ;
_v622
505 0 _aOvarian Cancer Detection and Pathogenesis -- Potential and Limitations in Early Diagnosis of Ovarian Cancer -- SMRP and HE4 as Biomarkers for Ovarian Carcinoma When Used Alone and in Combination with CA125 and/or Each Other -- Classification of Ovarian Cancer: A Genomic Analysis -- Epigenetic Markers of Ovarian Cancer -- Role of Genetic Polymorphisms in Ovarian Cancer Susceptibility: Development of an International Ovarian Cancer Association Consortium -- MicroRNA in Human Cancer: One Step Forward in Diagnosis and Treatment -- Ovarian Carcinogenesis: An Alternative Hypothesis -- BRCA1-Induced Ovarian Oncogenesis -- Role of p53 and Rb in Ovarian Cancer -- Ovulatory Factor in Ovarian Carcinogenesis -- Ovarian Cancer Therapeutics -- Gynecologic Oncology Group (GOG-USA) Trials in Ovarian Cancer -- Intraperitoneal Chemotherapy for Ovarian Cancer -- Ovarian Cancer: Can We Reverse Drug Resistance? -- Syngeneic Mouse Model of Epithelial Ovarian Cancer: Effects of Nanoparticulate Paclitaxel, Nanotax® -- Individualized Molecular Medicine: Linking Functional Proteomics to Select Therapeutics Targeting the PI3K Pathway for Specific Patients -- Defective Apoptosis Underlies Chemoresistance in Ovarian Cancer -- Nanoparticle Delivery of Suicide DNA for Epithelial Ovarian Cancer Therapy -- Biological Therapy with Oncolytic Herpesvirus -- Cancer Immunotherapy: Perspectives and Prospects -- Regulatory T Cells: A New Frontier in Cancer Immunotherapy -- Inhibitory B7 Family Members in Human Ovarian Carcinoma -- Role of Vascular Leukocytes in Ovarian Cancer Neovascularization -- Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a New Target Molecule for Cancer Therapy.
520 _aAegean Conferences is an independent, nonprofit, educational organization directed and managed by the scientific community. The board is made up of nine researchers/scientists in various disciplines from Harvard, Brown, University of Pennsylvania, UCSD, Princeton, Biovista and the Foundation for Biomedical Research Academy of Athens. The board both invites and approves unsolicited proposals for Conferences in all fields of Science, Engineering, Arts, and Humanities. The purpose of the Conferences is to bring together individuals with common interests to examine the emerging and most advanced aspects of their particular field. The Symposium on Ovarian Cancer: State of the Art and Future Directions intends to bring together international experts interested in the development of novel diagnostic, prognostic and therapeutic tools for ovarian cancer. The meeting will function as a think tank where clinicians, translational and basic scientists, and parties from the biotechnology and pharmaceutical industry will get together to review recent advances in clinical research and translational science in ovarian cancer and define areas of future research opportunities and priorities.
650 0 _aMEDICINE.
650 0 _aONCOLOGY.
650 0 _aLIFE SCIENCES.
650 1 4 _aBIOMEDICINE.
650 2 4 _aCANCER RESEARCH.
650 2 4 _aLIFE SCIENCES, GENERAL.
700 1 _aBerchuck, Andrew.
_eeditor.
700 1 _aOzols, Robert.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9780387689661
830 0 _aAdvances in Experimental Medicine and Biology,
_x0065-2598 ;
_v622
856 4 0 _uhttp://dx.doi.org/10.1007/978-0-387-68969-2
_zVer el texto completo en las instalaciones del CICY
912 _aZDB-2-SBL
942 _2ddc
_cER
999 _c58063
_d58063